Understand the company
Start with the business profile, the Reward and Risk scores, and the direction of the financials.
Research the whole company.Explore 7,800+ scored UK and US companies.
Start researching
Go beyond the ticker. Understand the business.
Bring fundamentals, valuation, forecasts, dividends, ownership, and the Openbook Reward and Risk scores together on one connected research page.
7,800+ scored UK and US companies · 8-factor Reward and Risk model · Educational research, not investment advice
AstraZeneca plc
Healthcare · Large-cap · London Stock Exchange
12,456p+9.3% over 12 months
Company research summary
From the Pro AI BriefAstraZeneca combines durable oncology growth and strong margins with a premium valuation. The central research question is whether pipeline delivery can sustain earnings growth as key products mature.
Revenue growth9.9%Supportive
Gross margin81.9%Strong
Forward P/E19.8xAbove sector
Openbook Reward and Risk
0-100Reward62Four reward factors
Risk35Four risk factors
Five-year revenue trend
USD billions2021202220232024Latest
What deserves attention
Research promptsPipeline execution
Late-stage assets are important to the next leg of growth.
Premium valuation
Current multiples leave less room for operational disappointment.
China exposure
Regulatory and operating uncertainty warrants monitoring.
Financial statements
Compare performance across consistent reporting periods.
QuarterlyAnnual
| USD millions | 2021 | 2022 | 2023 | 2024 | Latest |
|---|---|---|---|---|---|
| Revenue | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 |
| Gross profit | 24,846 | 31,803 | 37,208 | 43,192 | 48,115 |
| Operating income | 1,056 | 4,998 | 7,726 | 9,112 | 10,483 |
| Net income | 115 | 3,293 | 5,955 | 7,041 | 8,116 |
| Free cash flow | 3,528 | 5,742 | 7,613 | 8,421 | 9,104 |
Valuation context
View headline multiples against history and peers.
CurrentHistory
Forward P/E19.8x
Above five-year median
EV / EBITDA17.5x
Premium to sector
PEG ratio1.69x
Growth partly reflected
Analyst expectations
See what the market currently expects from the business.
Next year3 years
Revenue estimate$63.2B+7.6% expected growth
EPS estimate$9.14+12.6% expected growth
Consensus target14,000p12.4% above current price
Estimate revisionsPositive6 upgrades over 90 days
Risk score breakdown
The four factors behind the 0-100 Openbook Risk score.
FactorsHistory · Pro
Volatility
How much the share price moves. The largest single weight in the Risk score.
Financial solvency
Whether the balance sheet can carry what the company owes.
Operational quality
How consistent the business is in its operations.
Size factor
Where the company sits on the size scale.
1,400+UK companies scored
6,300+US companies scored
One pagefor the whole company story
Plain Englishalongside the underlying data
See the financial story, not just the latest number.
Move from the income statement to margins, cash flow, and balance-sheet trends without rebuilding the company in a spreadsheet.
- Compare annual and quarterly performance consistently.
- Connect revenue growth to margins, earnings, and cash generation.
- Spot changes that deserve a closer look.
Revenue and operating profit
Five-year viewRevenueOperating profit
Know what the market is already pricing in.
A multiple means little on its own. Put valuation beside growth, history, and relevant peers to understand where expectations may be demanding.
- Compare common multiples across peer companies.
- See whether a stock trades above or below its own history.
- Connect valuation to the growth assumptions behind it.
Forward P/E peer comparison
Illustrative healthcare peersGSK
12.4x
Sanofi
14.1x
AstraZeneca
19.8x
Novo Nordisk
22.3x
Eli Lilly
31.6x
Research both sides of the investment case.
Keep the reasons a company could outperform beside the assumptions and risks that could prove the thesis wrong.
- Separate business catalysts from share-price momentum.
- Turn broad concerns into specific research questions.
- Review what evidence would change your view.
Investment case
AI Brief example · ProPotential catalysts
Oncology portfolio growth
Durable demand across core medicines could support continued revenue expansion.
Late-stage pipeline
Successful readouts and launches could extend the growth runway.
Margin progression
Operating leverage may convert growth into faster earnings expansion.
Questions and risks
Execution expectations
A premium valuation raises the cost of delayed trials or weaker launches.
Regulatory exposure
Policy and operating uncertainty can affect important markets.
Product concentration
Dependence on major franchises increases sensitivity to competition.
Read the current story, and the case against it.
Four AI agents read recent coverage on a company and set out where it stands today, a bull case, a bear case, and the key risks. The AI reads the coverage; it does not write it.
- Get the current story on a company in plain English.
- Weigh a stated bull case against a stated bear case.
- Treat the key risks as a route into deeper research, not a recommendation.
AI Brief
Pro featureCurrent story
Product mix has shifted toward higher-margin oncology medicines, revenue has grown faster than parts of the operating cost base, and cash conversion has remained supportive. The next question is whether that leverage can continue as launch spending rises.
Current storyBull caseBear caseKey risks
From first look to informed view.
Openbook organises the research journey so you can move from a quick orientation to the questions that matter most.
Test the expectations
Review financial statements, analyst forecasts, valuation history, and peer context together.
Form your own view
Balance catalysts against risks, investigate the evidence, and decide what would change your thesis.
Deep Stock Research, explained.
A research page has its own tabs: Overview, Reward, Risk, Chart, Fundamentals, Valuation, Community, Ownership, Dividends and Forecasts. Pro accounts also get the AI Brief. What is available varies by security type — funds and ETFs are scored differently from shares, and funds carry a 1-7 risk level rather than a Reward score.
Openbook is built for UK investors and covers both London- and US-listed companies. 1,488 UK-listed and 6,325 US-listed companies carry a full Reward and Risk score, within a searchable universe of 26,900+ instruments that also includes ETFs and funds. US score coverage is still expanding, so a company with too little history shows a blank rather than an estimate.
Where available, Openbook organises consensus estimates and related context so you can see what the market expects. Forecasts are uncertain and should be reviewed alongside the assumptions and risks around them.
The AI Brief is a Pro feature on instrument pages. Four AI agents read recent coverage and set out the current story, a bull case, a bear case and the key risks in plain English. It is a route into the underlying data, not a replacement for it, for independent judgement, or for professional advice.
No. Openbook provides educational and informational research tools, not personal financial advice or investment recommendations. You should conduct your own research and consider your circumstances before making decisions.
One company. One connected research view.
Go from headline numbers to the financial story, expectations, valuation, and risks behind them.